Angelini Ventures

Angelini Ventures is the corporate venture capital arm of Angelini Industries, founded in 2021 and headquartered in Rome, Italy. With a capital commitment of €300 million, Angelini Ventures focuses on early-stage investments in biotechnology, digital health, and life sciences. The firm aims to leverage technology to improve healthcare, reshape patient journeys, and address unmet needs in vulnerable populations. The firm has made significant investments globally, including in Europe, North America, and Israel, with a particular emphasis on brain health and consumer segments such as women, children, and the elderly. Notable portfolio companies include Pretzel Therapeutics, Argobio, Serenis, and Nouscom. Angelini Ventures is led by CEO Paolo Di Giorgio, who has extensive experience in the pharmaceutical and investment sectors. The team includes experts such as Elia Stupka, Managing Director, and Gabriela Manrique, Partner, among others, spread across major innovation hubs globally​.